CanSinoBIO Announces Approval for Its Group A and Group C Meningococcal Conjugate Vaccine in China
Tianjin, June 23, 2021

CanSino Biologics Inc. (“CanSinoBIO”) (SHSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China (“NMPA”) granted approval for its Group A and Group C Meningococcal Conjugate Vaccine (CRM197) (“MCV2”, trade name: Menphecia).
Menphecia provides protection against infection of Group A and C neisseria meningitidis. CanSinoBIO significantly improved the product quality and safety profile by using CRM197 as a protein carrier and excluding animal-origin ingredients in culturing. Based on the polysaccharide-protein conjugate technology, Menphecia overcomes the weaknesses of traditional Meningococcal Polysaccharide Vaccine (“MPV”), enhances the induced immune response and provides stronger immune protection.

According to the results of phase III clinical trial, comparing to the other granted MCV2 vaccines in China, Menphecia has a better safety profile in the 3 months old participant group, and better immunogenicity of Group A meningococcus in the 6 to 11 months old and 12 to 23 months old participant groups.

Meningococcal disease is a highly infectious disease caused by Neisseria meningitidis. Without timely treatment, the fatality rate can reach between 20% and 35% among infants below 12 months old.

Currently, vaccination is the most efficient way to prevent meningococcal disease. Today, every child below 6 years old needs to have the MCV vaccine, according to the national immunization program of China. For children below 2 years old, Menphecia or other MCV2 vaccines could be a better option than traditional MPV vaccines. The prevention of meningococcal disease through vaccination has been driving the significant growth of the Chinese meningococcal vaccine market.